Wells Fargo becomes bullish on this biotech company

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 72%

Health Care Industry News

Neurocrine Biosciences Inc,Wells Fargo & Co,Stock Markets

Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday's close. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.

"We think Crinecerfont is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Elsewhere in the company's pipeline, Neurocrine's depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opoprtunity.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in CA
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Canada Canada Latest News, Canada Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

S&P 500 target raised to 5500+ at Wells Fargo on strong earnings growthS&P 500 target raised to 5500+ at Wells Fargo on strong earnings growth
Source: Investingcom - 🏆 450. / 53 Read more »